Should Passive Income Investors Buy Clorox Stock? | CLX Stock
Summary
Parkev Tatevosian, CFA argues that Clorox is currently navigating a difficult period characterized by high inflation, which is expected to exceed $200 million in fiscal year 2027, and geopolitical tensions impacting supply chains. Parkev Tatevosian, CFA states that the management team’s performance during the pandemic was below average, as they struggled to maintain margins despite a massive surge in demand. Currently, operating margins remain well below pre-pandemic levels, and sales growth is forecasted to be nearly flat.
However, Parkev Tatevosian, CFA states that the current valuation of Clorox reflects these headwinds, with the stock trading at a forward price-to-earnings ratio of 17. Parkev Tatevosian, CFA argues that the intrinsic value of the stock is significantly higher than its current market price, offering a potential 33% upside. Parkev Tatevosian, CFA recommends that investors consider dollar-cost averaging into the stock throughout the fiscal year while the price remains discounted.
Mentioned Stocks
Reasoning: Parkev Tatevosian, CFA argues that Clorox is a buying opportunity despite a projected $200 million inflationary hit and weak 1-2% sales growth forecasts. Parkev Tatevosian, CFA notes that the stock's forward P/E of 17 is near historic lows, suggesting the market has already priced in the negative macroeconomic environment. Parkev Tatevosian, CFA calculates a 33% upside over the next 12 to 18 months and suggests dollar-cost averaging as a strategy for investors.